Total synthesis

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Retrieved on: 
Wednesday, July 21, 2021
Bryostatin, Macrolides, Total synthesis

The U.S. toll free dial-in for the conference call is (877) 407-9205, and the international dial-in number is 1-(201)-689-8054.

Key Points: 
  • The U.S. toll free dial-in for the conference call is (877) 407-9205, and the international dial-in number is 1-(201)-689-8054.
  • Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
  • Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease.
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Retrieved on: 
Wednesday, July 14, 2021
Branches of biology, Health sciences, Biology, Bryostatin, Macrolides, Total synthesis, Pharmacognosy, Neuroscience, Alzheimer's disease, Drug discovery, Neurodegeneration

The Company's lead drug candidate, Bryostatin-1, will be featured in a poster presentation entitled: "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease ("AD") Patients: A Regenerative Therapeutic Strategy."

Key Points: 
  • The Company's lead drug candidate, Bryostatin-1, will be featured in a poster presentation entitled: "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease ("AD") Patients: A Regenerative Therapeutic Strategy."
  • Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
  • Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease.
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.

Bio-Vanillin Market Research Report 2021 - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 8, 2021
Chemicals, Plastics, Manufacturing, Hydroxybenzaldehydes, Flavors, Chemistry, Physical sciences, Total synthesis, Vanilla, Vanillin, Vanilloids

The "Bio-Vanillin Market Research Report by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bio-Vanillin Market Research Report by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • The Global Bio-Vanillin Market size was estimated at USD 203.32 Million in 2020 and expected to reach USD 216.78 Million in 2021, at a Compound Annual Growth Rate (CAGR) 6.96% from 2020 to 2026 to reach USD 304.46 Million by 2026.
  • In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.
  • The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Bio-Vanillin Market, including

Oral Nanoparticle-Encapsulated Bryostatin-1 Found Effective for Treating Cognitive Deficits in an Alzheimer’s disease Mouse Model

Retrieved on: 
Tuesday, May 4, 2021
Engineering, Health, Manufacturing, General Health, Research, Science, Bryostatin, Macrolides, Total synthesis, LSU Health Sciences Center, Aphios Corporation:, LSU HEALTH SCIENCES CENTER, APHIOS CORPORATION:

AD transgenic mice were treated with a nanoparticle encapsulated Bryostatin-1 three times the week before testing and then daily for five days of testing.

Key Points: 
  • AD transgenic mice were treated with a nanoparticle encapsulated Bryostatin-1 three times the week before testing and then daily for five days of testing.
  • Across the acquisition phase, we observed that mice treated with nanoencapsulated Bryostatin-1 had shorter latencies, increased time in the target zone and decreased time in the opposite quadrant.
  • Mice were also given one day of retention testing after a 2-week period without drug.
  • The content of this release is solely the responsibility of the authors and does not represent the official views of NIA and NIH.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504005455/en/\n"

Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum

Retrieved on: 
Monday, April 26, 2021
Branches of biology, Natural sciences, Chemistry, Bryostatin, Macrolides, Total synthesis, Alzheimer's disease, Amyloidosis, Proteins, Amyloid beta, Tau protein, Preclinical development

Regenerative efficacy of bryostatin, and other Synaptogenix platform drugs, is complemented by other demonstrated efficacies to prevent neuronal death, reduce A Beta-oligomers, and reduce tau phosphorylation in pre-clinical AD models.

Key Points: 
  • Regenerative efficacy of bryostatin, and other Synaptogenix platform drugs, is complemented by other demonstrated efficacies to prevent neuronal death, reduce A Beta-oligomers, and reduce tau phosphorylation in pre-clinical AD models.
  • Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD.
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.
  • Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over.

Mass General Brigham Physicians Call for Elimination of Harmful Language in Clinical Medicine

Retrieved on: 
Friday, April 9, 2021
Chemistry, Health sciences, Physical sciences, Total synthesis, Vancomycin, Johns Hopkins School of Medicine, Antibiotic, Racism, Syndrome

The article focuses on terminology used to describe a drug reaction to Vancomycin, the most commonly used antibiotic in U.S. hospitals.

Key Points: 
  • The article focuses on terminology used to describe a drug reaction to Vancomycin, the most commonly used antibiotic in U.S. hospitals.
  • Santiago AlvarezArango, MD, allergy specialist and Clinical Pharmacology Fellow at Johns Hopkins School of Medicine, was the first author of both that prior study and this perspective.
  • They propose five critical steps to achieving this goal:
    Physicians need to stop teaching Red Man Syndrome and using it in clinical practice.
  • The elimination of harmful terminology like Red Man Syndrome is consistent with Mass General Brighams United Against Racism strategic initiative ,a commitment to eliminate the many impacts that racism has on patients and employees within the Mass General Brigham system.

Synaptogenix Announces Phase 2b Bryostatin-1 Clinical Trial Update

Retrieved on: 
Thursday, April 1, 2021
Branches of biology, Health sciences, Health, Clinical research, Bryostatin, Macrolides, Total synthesis, Alzheimer's disease, Neurodegeneration, Clinical trial, Placebo

NEW YORK, April 1, 2021 /PRNewswire/ -- Synaptogenix, Inc.(OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institute of Health ("NIH") sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease ("AD").

Key Points: 
  • NEW YORK, April 1, 2021 /PRNewswire/ -- Synaptogenix, Inc.(OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institute of Health ("NIH") sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease ("AD").
  • By having adequate safeguards against baseline imbalance and a more conventional six-month duration trial, we expect to avoid any issues with placebo effects.
  • Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease.
  • These forward-looking statements include statements regarding the Phase 2 clinical trial of Bryostatin-1 and further studies, and continued development of use of Bryostatin-1 for AD and other cognitive diseases.

Aphios Granted US Patent for Novel, More Potent Bryoid to Treat Alzheimer’s diseases, HIV-1 Latency, Prostate Cancer, Glaucoma and Multiple Sclerosis

Retrieved on: 
Tuesday, March 30, 2021
Biotechnology, Pharmaceutical, Optical, Oncology, Health, Mental health, Infectious diseases, Other Health, Bryostatin, Macrolides, Total synthesis, Chemistry, Patent, Prostate cancer

Aphios Corporation announced today that it has been granted United States Patent No.

Key Points: 
  • Aphios Corporation announced today that it has been granted United States Patent No.
  • This patent is part of a family of Aphios patents in Europe (Patent No.
  • Twenty-one Bryoid compositions, known as Bryostatins and are numbered 1-21, not including the present novel Bryostatin, have been identified.
  • Aphios is developing Bryoids as therapeutics for neurodegenerative diseases such as Alzheimers disease, Multiple Sclerosis, prostate cancer, glaucoma and HIV-1 latency.

Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference

Retrieved on: 
Friday, February 12, 2021
Natural sciences, Health sciences, Life sciences, Pharmaceutical industry, Bryostatin, Macrolides, Total synthesis, Medication, Orphan drug

The Winter Wonderland "Best Ideas from the Buyside" conference will be held February 16ththrough 19th, 2021 with 25-minute virtual presentations on the 16th and 17th, and one-on-ones for qualified institutional investors on the 18th and 19th.

Key Points: 
  • The Winter Wonderland "Best Ideas from the Buyside" conference will be held February 16ththrough 19th, 2021 with 25-minute virtual presentations on the 16th and 17th, and one-on-ones for qualified institutional investors on the 18th and 19th.
  • Please visit the event website at https://microcaprodeo.com to register for the conference and schedule a one-on-one meeting with Synaptogenix.
  • Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel neuro-regenerative drug therapies for neurodegenerative diseases.
  • The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome.

Synthetic Bryostatin Available to Expand Neurodegenerative Indication Trials

Retrieved on: 
Thursday, February 4, 2021
Bryostatin, Macrolides, Total synthesis, Degenerative disease, Chemistry, Natural sciences, Physical sciences

NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Synaptogenix, Inc.(OTC: SNPX) announced today that it has received its first batch of synthetic Bryostatin.

Key Points: 
  • NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Synaptogenix, Inc.(OTC: SNPX) announced today that it has received its first batch of synthetic Bryostatin.
  • The Company has an exclusive licensing agreement with Stanford University ("Stanford") for synthetic Bryostatin for all neurologic indications, as well as a supply agreement in place with Bryologyx, Inc. as previously announced.
  • To date, Synaptogenix has relied upon supply of Bryostatin, derived from natural sources, from the National Cancer Institute of Health.
  • "Our new supply of synthetic Bryostatin allows Synaptogenix to conduct trials to potentially treat a broad range of neurodegenerative disorders including Multiple Sclerosis, Stroke, Parkinson's disease, Traumatic Brain Injury, and Fragile X / Autistic Spectrum Disorder," stated Daniel L. Alkon, MD, President and CSO.